Diabetes mellitus, platelet function and acetylsalicylic acid

Main Article Content

G.F. Gendeleka
A.N. Gendeleka

Abstract

Diabetes mellitus is an independent risk factor for cardiovascular disease (CVD). Accelerated development of atherosclerosis in patients with diabetes is a consequence of endothelial dysfunction, low-grade inflammation, oxidative stress, dyslipidemia, and platelet dysfunction. The results of studies have shown that among diabetic patients there is a high percentage of no effect when using both acetylsalicylic acid (ASA) and clopidogrel. It is necessary to distinguish between patients with a weak response and people with no effect — resistant to aspirin. The frequency of the so-called aspirin resistance, according to modern research, is different and depends on the methods used to study platelet function. In diabetic patients, it ranges from 5 to 45 % when taking ASA and from 4 to 30 % when taking clopidogrel. Recent studies show an even higher proportion of such individuals among people with diabetes. The appropriateness of lifelong ASA for secondary prevention in people diagnosed with CVD is indisputable (level of evidence A). At the same time, approaches to primary prevention vary in different countries. It is emphasized that the primary prevention with ASA in modern conditions maintains a favorable balance of benefits/risks. The new guidelines state that the calculated 10-year risk of cardiovascular events should not be considered when deciding whether to prescribe ASA to patients without CVD. Instead, all risk factors present in each patient should be considered, including burdensome family history, inability to achieve lipid and glycemic levels, and coronary calcification. The conclusion that ASA has evidence-based efficacy in secondary prophylaxis in patients with CVD has been confirmed. Regarding the primary prevention of cardiovascular events, including healthy individuals, the appropriateness, duration of administration, and choice of ASA should be determined taking into account the 10-year development of serious events, the presence of comorbidities, and the risk of bleeding.

Article Details

How to Cite
Gendeleka, G., and A. Gendeleka. “Diabetes Mellitus, Platelet Function and Acetylsalicylic Acid”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 3, June 2021, pp. 250-7, doi:10.22141/2224-0721.17.3.2021.232660.
Section
Literature Review

References

De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front Endocrinol (Lausanne). 2018 Jan 17;9:2. doi:10.3389/fendo.2018.00002.

Koval SM, Yushko KO, Snihurska IO, et al. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertension 2019;23(3):183-189. doi:10.5603/AH.a2019.0012.

Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020 Mar 6;21(5):1835. doi:10.3390/ijms21051835.

Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb. 2018 Jan 1;25(1):27-39. doi:10.5551/jat.RV17014.

Santilli F, Simeone P, Liani R, Davì G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat. 2015 Jul;120:28-39. doi:10.1016/j.prostaglandins.2015.05.002.

Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018 Aug 31;17(1):121. doi:10.1186/s12933-018-0763-3.

Fidler TP, Marti A, Gerth K, et al. Glucose Metabolism Is Required for Platelet Hyperactivation in a Murine Model of Type 1 Diabetes. Diabetes. 2019 May;68(5):932-938. doi:10.2337/db18-0981.

Suslova TE, Sitozhevskii AV, Ogurkova ON, et al. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. Front Physiol. 2015 Jan 5;5:501. doi:10.3389/fphys.2014.00501.

Asrat D, Tesfaye G, Gedefaw L, Addisu W, Yemane T. Hemostatic Abnormality and Associated Factors in Diabetic Patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia: A Comparative Cross-sectional Study. Ethiop J Health Sci. 2019 Mar;29(2):251-258. doi:10.4314/ejhs.v29i2.12.

Eleftheriadou I, Tentolouris A, Grigoropoulou P, et al. The association of diabetic microvascular and macrovascular disease with cutaneous circulation in patients with type 2 diabetes mellitus. J Diabetes Complications. 2019 Feb;33(2):165-170. doi:10.1016/j.jdiacomp.2018.10.008.

Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229-236. doi:10.1615/CritRevEukaryotGeneExpr.2017019712.

Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010 Mar;11(1):61-74. doi:10.1007/s11154-010-9134-4.

American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S86-S104. doi:10.2337/dc18-S009.

Bliden KP, Patrick J, Pennell AT, Tantry US, Gurbel PA. Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. Future Cardiol. 2016 Jan;12(1):45-58. doi:10.2217/fca.15.60.

Fernández-Ruiz I. Aspirin for primary prevention of CVD: a matter of balance. Nat Rev Cardiol. 2018 Nov;15(11):651. doi:10.1038/s41569-018-0096-7.

Santulli G. In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years. Ann Intern Med. 2018 Dec 18;169(12):JC67. doi:10.7326/ACPJC-2018-169-12-067.

Gaziano JM, Brotons C, Coppolecchia R, et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018 Sep 22;392(10152):1036-1046. doi:10.1016/S0140-6736(18)31924-X.

ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi:10.1056/NEJMoa1804988.

McNeil JJ, Nelson MR, Woods RL, et al; ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi:10.1056/NEJMoa1803955.

De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009 Nov 6;339:b4531. doi:10.1136/bmj.b4531.

Ogawa H, Nakayama M, Morimoto T, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 Nov 12;300(18):2134-41. doi:10.1001/jama.2008.623.

Belch J, MacCuish A, Campbell I, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 Oct 16;337:a1840. doi:10.1136/bmj.a1840.

Fowkes FG, Price JF, Stewart MC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010 Mar 3;303(9):841-8. doi:10.1001/jama.2010.221.

Welin L, Wilhelmsen L, Björnberg A, Odén A. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1143-9. doi:10.1002/pds.1828.

Schrör K, Nitschmann S. Importance of acetylsalicylic acid in primary prevention : ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al. Internist (Berl). 2019 Feb;60(2):209-216. doi:10.1007/s00108-018-0541-z. (in German).

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127(3):377-85. doi:10.1161/CIRCULATIONAHA.112.117283.

Ridker PM. Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? N Engl J Med. 2018 Oct 18;379(16):1572-1574. doi:10.1056/NEJMe1812000.

Thabah MM, Sharma R. Aspirin for primary prevention of cardiovascular disease events in diabetes: the balancing act? J R Coll Physicians Edinb. 2018 Dec;48(4):332-333. doi:10.4997/JRCPE.2018.410.

Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun 21;164(12):804-13. doi:10.7326/M15-2113.

Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60. doi:10.1016/S0140-6736(09)60503-1.

Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 Nov 29;124(22):2458-73. doi:10.1161/CIR.0b013e318235eb4d.

Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Jun 21;164(12):836-45. doi:10.7326/M16-0577.

Piepoli MF, Hoes AW, Agewall S, et al; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi:10.1093/eurheartj/ehw106.

de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001 Jan 13;357(9250):89-95. doi:10.1016/s0140-6736(00)03539-x.

Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352(13):1293-304. doi:10.1056/NEJMoa050613.

Belch J, MacCuish A, Campbell I, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 Oct 16;337:a1840. doi:10.1136/bmj.a1840.

Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014 Dec 17;312(23):2510-20. doi:10.1001/jama.2014.15690.

Van't Hof JR, Duval S, Walts A, Kopecky SL, Luepker RV, Hirsch AT. Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007-2015: A Serial, Cross-sectional Study. J Am Heart Assoc. 2017 Oct 3;6(10):e006328. doi:10.1161/JAHA.117.006328.

Raju N, Sobieraj-Teague M, Bosch J, Eikelboom JW. Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. Am J Med. 2016 May;129(5):e35-6. doi:10.1016/j.amjmed.2015.10.046.

Desideri G, Ferri C. Aspirin for primary prevention in elderly hypertensive patients: to treat or not to treat? J Hypertens. 2019 Jun;37(6):1154-1156. doi:10.1097/HJH.0000000000002059.

Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019 Nov 4;17(1):198. doi:10.1186/s12916-019-1428-0.